ArcGen Bioscience

Lego Chem Bioscience , a company created by people with dreams and enthusiasm for global new drug development, will open up new horizons in Korean new drug development based on systematic drug development system and core technology.

April Bio is a drug development company that develops antibodies and long-acting biologics.

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

LabGenomics is a healthcare company specialized in molecular diagnostics.

Galaxy operates a pharmaceutical research and development company for the treatment of encephalopathy and oncology diseases. The company focuses on creating remedies for challenging brain conditions like dementia, thereby assisting healthcare professionals in enhancing human well-being and overall quality of life.

SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable for patients in need. The company was established in 2016 and is headquartered in Seoul, South Korea.

Shaperon is a clinical-stage biotech company that develops inflammasome inhibitors.

SN BioScience provide nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA), peptide and protein to deliver in the form of nano-micelle, nanoparticle or liposome. Their proprietary “double core-shell technology” and pool of acceptable lipids and polymers could help your research that having difficulties in solubility or delivery.

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

NOUS is a biotech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical Market. Our first product is Mindave, a caffeine alternative that enhances cognitive and physical performance, improving memory, concentration and reflexes without causing the typical adverse effects of caffeine such as blood pressure spikes or tachycardia, and improves gastrointestinal well-being. A recent functional study demonstrated the effectiveness of Mindave on cognitive function, showing benefits even superior to caffeine. Worldwide, 709 million people should avoid caffeine due to gastrointestinal or heart problems. However, there is currently no viable, healthy and 100% natural alternative on the market to enable everyone to face each day with full energy. In addition, the rapid changes in consumer needs and market trends pose a major challenge to medium and large companies who are unable to respond quickly to the constant new product launches. We are targeting companies with a clear health mission, enabling us to help consumers live better. Our ideal customers are beverage and food companies for developing new functional products, ingredient companies for exponential distribution through consolidated networks, and fitness companies. Being selected for the Plag&Play accelerator programme in San Francisco has opened the door to the American market and after filling the international patent in December 2023, we started the commercialisation in January 2024. To date we have +11 LOIs from customers, 5 POCs underway with ITA and US companies, 1 contract for product development consultancy with a startup and 1 ingredient company selling Mindave as part of their portfolio, allowing us to benefit from their network. We are firm believers in the link between human health and the environment’s health. With Mindave, we estimate -40% of water waste, -30% of deforestation and -30% of CO2 emissions at full production compared to coffee farming. Our focus on sustainable innovation leads us to develop new by-products from upcycling every year until we reach zero waste by 2027. We forecast the development of at least 5 products by 2027. Inspired by nature, we aim to innovate the F&B sector while reducing environmental impact.

AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes attached to molecules, which can deliver targeted radiation to tumors at the molecular level. This approach enables healthcare providers to offer safe and efficient treatment options for various types of cancer.